Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Deepak L. Bhatt(Mount Sinai Hospital), Mark Napoli, Antonio Blanco, Kausik K. Ray(Imperial College London), Timothy J. Gardner(Uppsala University), Kim Fox(Royal Brompton Hospital), Alexander Parkhomenko, Jay Stone(Community Medical Center), Barry Bertolet, W. Herbert Haught, Ramin Manshadi, Dharam J. Kumbhani(Southwestern Medical Center), Ashit Jain, Irina Lendel, Khaled Nour(Wayne State University), Carlos Vaca(Ministerio de Salud), Louis Kantaros, Marielle Andersson(AstraZeneca (Sweden)), Dominick J. Angiolillo(University of Florida), Wilhelm Ridderstråle(AstraZeneca (Brazil)), Supratim Banerjee(Indian Institute of Science Education and Research Kolkata), R. Passi, Dustin Thomas, Francisco Padrón, Michael Pursley(The Heart House), Anders Himmelmänn(AstraZeneca (Sweden)), Mikhail Kosiborod(AstraZeneca (Brazil)), Satinder Saini, George Kichura, Harinder Gogia, Darren K. McGuire(Parkland Health & Hospital System), Stefan James(Uppsala University), Lawrence A. Leiter(St. Michael's Hospital), James Bennett, Amaury Roman-Miranda(Stanford University), Manuel Bouza, Claes Held(Uppsala University), Robert A Harrington(Center for Clinical Research (United States)), Tabassome Simon(Sorbonne Université), Yang Song(Baim Institute for Clinical Research), Shamir R Mehta(Population Health Research Institute), Wenwu Zhang, Robert Black, Michael D'Urso, Philippe Gabríel Steg(Mount Sinai Hospital), Michael Russo, Vladimir Santos
The Lancet
September 1, 2019
Cited by 212


Related Papers